T2 Biosystems (NASDAQ:TTOO – Get Free Report) announced its earnings results on Monday. The medical equipment provider reported ($0.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.97) by $0.31, Yahoo Finance reports. The business had revenue of $1.95 million for the quarter. T2 Biosystems updated its FY 2024 guidance to EPS.
T2 Biosystems Stock Performance
T2 Biosystems stock traded up $0.03 during midday trading on Tuesday, reaching $4.77. The stock had a trading volume of 143,821 shares, compared to its average volume of 272,518. T2 Biosystems has a 52-week low of $2.60 and a 52-week high of $70.00. The company has a fifty day moving average of $5.12 and a 200 day moving average of $4.47.
Analyst Ratings Changes
Separately, Canaccord Genuity Group upped their target price on shares of T2 Biosystems from $3.00 to $5.00 and gave the company a “hold” rating in a research report on Tuesday.
T2 Biosystems Company Profile
T2 Biosystems, Inc, an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine.
Read More
- Five stocks we like better than T2 Biosystems
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- This Semiconductor Stock Is ON Track for a New High
- What is Insider Trading? What You Can Learn from Insider Trading
- Why SoFi Stock is an Unmissable Growth Opportunity
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Has Micron’s Stock Drop Turned Into A Screaming Buy?
Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.
